Integrated Assessment of Antioxidant Activity and HPTLC Fingerprinting of <i>Nishaamalaki Churna</i>: A Multifaceted Approach

Background: Nishaamalaki churna is a classical ayurvedic formulation comprising Haridra (Curcuma longa L.) and Aamalaki (Phyllanthus emblica L.). It is traditionally prescribed in the management of Madhumeha (diabetes mellitus) in the Charaka Samhita. Aim: This study aimed to scientifically validate Nishaamalaki Churna (NC) through analytical standardisation and antioxidant profiling, focusing on quantifying curcuminoids and gallic acid. Methods: Organoleptic characteristics and physicochemical parameters were evaluated as per Ayurvedic Pharmacopoeia standards. Quantification of curcuminoids and gallic acid was performed using HPTLC. Antioxidant potential was assessed through multiple in vitro assays, including DPPH, FRAP, ABTS, and Lipid Peroxidation (LPO) inhibition, along with Total Phenolic Content (TPC) estimation. Results: NC exhibited a yellowish colour, characteristic odour, and sour taste. Physicochemical parameters were within pharmacopeial limits (pH-3.91, LOD-4.6%, total ash-8.23%, water-soluble extractive-47.62%). HPTLC quantified curcuminoids (10.44 mg/g) and gallic acid (5.295 mg/g). The formulation exhibited strong antioxidant activity, DPPH (IC50 84 ?g/mL), FRAP (100.00 mg GAE/g (IC50 41.7 ?g/mL), LPO (IC50 290 ?g/mL) and TPC (7.63 mg GAE/g). Confirming its potent redox-modulating and therapeutic potential. Conclusion: NC contains substantial amounts of bioactive curcuminoids and gallic acid, contributing to its antioxidant, anti-inflammatory, and antidiabetic properties. These findings scientifically substantiate its traditional therapeutic application in managing Madhumeha and oxidative stress�mediated disorders. Major Findings: The study established the analytical standardisation and antioxidant profile of NC, confirming the presence of key bioactive markers, curcuminoids (10.44 mg/g) and gallic acid (5.9 mg/g). The formulation demonstrated potent antioxidant activity across DPPH, FRAP, ABTS, and LPO assays.

View article page

Download PDF